Full-Time

Staff Accountant

Posted on 9/15/2025

ProKidney

ProKidney

201-500 employees

Develops cell therapy to treat CKD

No salary listed

No H1B Sponsorship

Winston-Salem, NC, USA

In Person

Category
Accounting (2)
,
Required Skills
Excel/Numbers/Sheets
Requirements
  • A Bachelor’s degree in Accounting, Finance, or related field.
  • Three or more years of general accounting experience.
  • Experience in payroll processing.
  • Strong knowledge of accounting principles and practices.
  • Proficiency in Microsoft Excel and accounting software.
  • Excellent attention to detail, accuracy, and organizational skills.
  • Ability to handle confidential information with integrity.
  • Strong communication and interpersonal skills.
  • Applicants must be eligible to work in the United States without the need for work visa or residency sponsorship.
Responsibilities
  • Perform general ledger activities, including journal entries, intercompany transactions, and account reconciliations for multiple entities.
  • Support the preparation of monthly, quarterly, and annual financial statements.
  • Assist with external and internal audit requests.
  • Participate in process improvement initiatives to drive efficiency and strengthen internal controls.
  • Process vendor invoices during peak times, ensuring accuracy, compliance, and timely payments.
  • Maintain vendor records and resolve vendor inquiries.
  • Reconcile invoices, purchase orders, and payments to ensure accuracy.
  • In the absence of the Accounts Payable Lead, process electronic payments and transfers.
  • Review and process employee expense reports via Certify and manual submissions.
  • Manage clinical study site payments and prepare remittance submissions.
  • Prepare monthly credit card accruals and reconcile actual charges.
  • Generate AP-related reports and support audits as needed.
  • Ensure accurate and timely bi-weekly payroll processing in the absence of the Payroll Manager.
  • Maintain employee payroll records and ensure compliance with federal, state, and local payroll regulations.
  • Support payroll functions including deductions, benefits, and garnishments.
  • Respond to payroll-related employee inquiries and resolve issues promptly.
  • Assist in preparing payroll reports and maintaining accurate documentation.
Desired Qualifications
  • Experience with Paylocity payroll software preferred.
  • Experience with SAGE X3 Enterprise Resource Planning system preferred.
  • Prior experience in a multi-faceted role with exposure to multiple accounting functions preferred.

ProKidney develops rilparencel, a cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD). The product is in late-stage clinical trials, and the goal is to delay or potentially avoid the need for dialysis by slowing the loss of kidney function. The treatment works by using transplanted or administered cells to support kidney tissue and function, offering a therapeutic option beyond standard care. ProKidney plans to commercialize rilparencel through sales to healthcare providers and direct-to-patient access, with potential partnerships with providers and insurers to expand access. The company differentiates itself by pursuing a first-in-class cell therapy specifically for CKD and focusing on a large, underserved patient population in the United States. Its mission is to transform CKD care by providing a treatment that preserves kidney function and reduces the burden of dialysis for millions of patients.

Company Size

201-500

Company Stage

IPO

Headquarters

Winston-Salem, North Carolina

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Phase 2 REGEN-007 showed statistically significant eGFR stabilization in Group 1.
  • PROACT 1 Phase 3 enrollment completes 2026 with data expected Q2 2027.
  • Appointed Greg Madison CCO with Genzyme blockbuster nephrology launch experience.

What critics are saying

  • BlackRock cut 73.9% PROK shares in Q2 2025 eroding institutional support.
  • Chief Regulatory Officer Weber sold 103,480 shares for $312,509 signaling doubts.
  • BofA Underperform rating at $1 target drives selloff before PROACT 1 readout.

What makes ProKidney unique

  • Rilparencel is first-in-class autologous cell therapy preserving kidney function in CKD.
  • Targets Stage 3b/4 CKD patients with diabetes, underserved by dialysis alternatives.
  • Received FDA RMAT designation accelerating approval for advanced CKD therapy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Flexible Work Hours

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Yahoo Finance
Mar 31st, 2026
ProKidney beats Q4 revenue estimates, advances rilparencel towards FDA approval

ProKidney Corp. announced fourth-quarter revenue of $893,000, beating consensus estimates of $600,000. The company provided updates on rilparencel, its chronic kidney disease treatment currently advancing through regulatory pathways. CEO Bruce Culleton highlighted 2025 achievements including positive Phase 2 study results for REGEN-007, FDA alignment on accelerated approval pathway, and strong enrolment for the Phase 3 PROACT 1 study. The company expects to complete PROACT 1 enrolment this year, with pivotal data expected in second quarter 2027. ProKidney develops cell therapies for chronic kidney disease, with rilparencel in Phase 3 clinical trials alongside various cryopreserved versions in different trial phases. The company aims to address treatment gaps for patients with advanced chronic kidney disease and diabetes at high risk of kidney failure.

The Associated Press
Mar 25th, 2026
ProKidney appoints Greg Madison as chief commercial officer to drive rilparencel strategy

ProKidney Corp, a late-stage cell therapy company focused on chronic kidney disease, has appointed Greg Madison as chief commercial officer. Madison will drive ProKidney's commercial strategy as the company advances towards potential commercialisation of rilparencel, its lead product candidate. Madison brings over 20 years of executive leadership experience in biopharmaceuticals. Most recently, he served as chief executive officer of Shield Therapeutics. He previously led Keryx Biopharmaceuticals, transforming it from clinical to commercial stage and launching a phosphate binder for dialysis patients. Earlier, he held senior roles at AMAG Pharmaceuticals and Genzyme, where he helped drive Renagel/Renvela to over $1 billion in annual revenue. ProKidney is developing rilparencel, an autologous cell therapy currently in Phase 3 trials for patients with advanced chronic kidney disease and type 2 diabetes.

MarketScreener
Mar 25th, 2026
ProKidney expands senior leadership team with appointment of Greg Madison as Chief Commercial Officer.

ProKidney expands senior leadership team with appointment of Greg Madison as Chief Commercial Officer. Published on 03/25/2026 at 04:01 pm EDT Acquiremedia WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) - ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Greg Madison as Chief Commercial Officer. In this role, Mr. Madison will drive ProKidney's commercial strategy as the Company advances towards the potential commercialization of rilparencel. "Greg is a seasoned commercial biopharma executive with a proven track record of building high-performing organizations, shaping strategy, and preparing innovative therapies for market," said Bruce Culleton, M.D., CEO of ProKidney. "He brings valuable operational and leadership skills needed to help guide ProKidney through its next phase of growth, including strong depth in nephrology and other specialty markets. As we advance our clinical and regulatory objectives for rilparencel, Greg will play a key role in strengthening our leadership team and positioning rilparencel for potential commercialization." Mr. Madison brings more than two decades of executive leadership experience across commercial strategy, general management, launch planning, business development, and company building in both clinical and commercial-stage biopharmaceutical companies. Most recently, he served as Chief Executive Officer of Shield Therapeutics plc, where he redesigned the commercial strategy, identified and led a transformative business development transaction, and raised capital to position the company on a path to profitability. Previously, he was Chief Executive Officer of Melt Pharmaceuticals, creating the company and advancing a novel sublingual combination drug from preclinical to Phase 2. Prior to that, he served as President and CEO of Keryx Biopharmaceuticals, leading its evolution from a clinical to commercial-stage organization, launching a novel iron-based phosphate binder for dialysis patients, and advancing a second indication for iron deficiency anemia. Earlier in his career, Mr. Madison was Executive Vice President and Chief Commercial Officer of AMAG Pharmaceuticals, and Vice President/General Manager of the Global Renal Business at Genzyme, where he helped drive Renagel/Renvela to blockbuster status with over $1 billion in annual revenue. "ProKidney is developing a truly novel cell therapy with the potential to address a profound unmet need for patients with advanced CKD and diabetes," said Greg Madison. "As a potential first cell therapy for CKD patients and nephrologists, I am excited to join the Company at such an important time. I look forward to working alongside Bruce and the broader team to shape the commercial strategy, organization, and execute the plans needed to support the potential launch of rilparencel." About Chronic Kidney Disease CKD is a progressive condition characterized by the gradual decline of kidney function, which can ultimately lead to end-stage kidney disease (ESKD) requiring dialysis or transplantation. An estimated 37 million adults in the U.S. have CKD, though many remain undiagnosed in the early stages. Diabetes is the leading cause of CKD, and individuals with both conditions face significantly elevated risks of cardiovascular events, hospitalization, and mortality. ProKidney is developing rilparencel for patients with Stage 3b/4 CKD and diabetes, a population that includes over 1 million people in the U.S. While current treatment options aim to slow disease progression, there remains a substantial unmet need for therapies that can stabilize kidney function and delay or prevent the need for dialysis in patients with advanced CKD. About ProKidney Corp. ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney's lead product candidate, rilparencel (also known as REACT(R), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com. Forward-Looking Statements This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. ProKidney's actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the advancement of our clinical and regulatory objectives for rilparencel and, if approved, potential commercialization of rilparencel. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: disruptions to our business or that may otherwise materially harm our results of operations or financial condition as a result of our recent domestication to the United States; the inability to maintain the listing of the Company's Class A common stock on Nasdaq; the inability of the Company's Class A common stock to remain included in various indices and the potential negative impact on the trading price of the Class A common stock if excluded from such indices; the inability to implement business plans, forecasts, and other expectations or identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry; the risk that results of the Company's clinical trials may not support approval; the risk that the FDA could require additional studies before approving the Company's drug candidates; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of Company to compete with other companies currently marketing or engaged in the biologics market and in the area of treatment of kidney diseases; the size and growth potential of the markets for the Company's products, if approved, and its ability to serve those markets, either alone or in partnership with others; the Company's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; the Company's intellectual property rights; uncertainties inherent in cell therapy research and development, including the actual time it takes to initiate and complete clinical studies and the timing and content of decisions made by regulatory authorities; the fact that interim results from our clinical programs may not be indicative of future results; the impact of geo-political conflict on the Company's business; and other risks and uncertainties included under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. ProKidney Contact Ethan Holdaway [email protected] Investor Relations Contact Daniel Ferry [email protected] Media Contact Audra Friis [email protected] 2026 GlobeNewswire, Inc., source Press Releases (C) Acquiremedia - 2026

Winston-Salem State University
Nov 11th, 2025
Greater Winston-Salem awards WSSU for innovation partnership in regenerative medicine project by National Science Foundation

Greater Winston-Salem awards WSSU for innovation partnership in regenerative medicine project by National Science Foundation. WSSU News & Information Winston-Salem State University is among the universities recognized with the "Truliant Collaboration of the Year" award by the Winston-Salem Chamber for its role in the groundbreaking National Science Foundation (NSF) Regenerative Medicine Engine. This national initiative unites key academic and industry leaders to advance regenerative medicine, a field that uses science and engineering to repair or replace damaged tissues and organs. WSSU joins the Wake Forest Institute for Regenerative Medicine (WFIRM), Forsyth Technical Community College, North Carolina Agricultural and Technical State University (N.C. A&T), Axiom Space, and the Regenerative Medicine Development Organization (ReMDO) as core partners. Funded through the NSF Engines Program, the collaboration will receive $15 million over the first two years, with potential support of up to $160 million over the next decade. The goal: to speed the development of regenerative medicine technologies from research to real-world application while driving workforce growth and economic opportunity across the Piedmont Triad and beyond. In its first year, the program has already produced measurable results, including creating more than 50 new jobs in central North Carolina, attracting nearly $300 million in new investments, and providing research, training, and internship opportunities for high school and college students preparing to enter the biotechnology workforce. As part of the initiative, Innovation, Translation, and Education Cores (ITECs) are being established at partner sites, including WSSU. Each core will focus on a different area of regenerative medicine such as biomaterials, workforce development or in-space manufacturing. These centers will help address pressing technical challenges and train a new generation of scientists and technicians. Dr. Jill Keith, WSSU's principal investigator for the NSF Engines program, plays a key leadership role in the effort. She is a biochemistry professor in WSSU's Department of Chemistry, interim director of the Biomedical Research Infrastructure Center, and an adjunct professor at Wake Forest University Health Sciences. "This project represents the power of collaboration," Keith said. "Through partnerships like this, our students and faculty are contributing to groundbreaking research that will shape the future of regenerative medicine and expand opportunities for underrepresented communities in STEM." The NSF Engines Program emphasizes inclusivity, ensuring that historically underrepresented populations in science and technology have access to education, training and leadership opportunities through its academic partners WSSU, N.C. A&T, and Forsyth Tech. "NSF's investment in innovation in the Piedmont Triad underscores the strength of collaboration between WSSU, WFIRM and N.C. A&T," said Shawn Holt, associate provost for Research & Innovation at WSSU. "It's also a testament to Dr. Keith's dedication to research and to preparing our students for meaningful careers in this rapidly growing field." Key areas in which the NSF Regenerative Medicine Engine is driving impact across the region include: * Accelerating innovation: ProKidney, a $500 million regenerative medicine company, has announced a $22.5 million expansion and plans to hire 50 skilled workers in Winston-Salem. * Growing investment: More than $266 million in new funding and in-kind resources have been secured since the program's launch in 2024. * Expanding partnerships: Over 150 industry, academic and community organizations are now part of the network. * Developing talent: New biotechnology internships and training programs are preparing high school and college students for careers in regenerative medicine. * Boosting the economy: The upcoming scale-up of regenerative medicine device manufacturing in 2025 is expected to create additional jobs and accelerate delivery of lifesaving products. NSF Director Sethuraman Panchanathan said the inaugural NSF Engines awards demonstrate a commitment to "create opportunity everywhere and enable innovation anywhere." He noted that these projects are helping transform entire regions into "world-leading hubs of innovation." More News. WSSU rams helping hands Food pantry ensures no ram goes hungry. Food insecurity affects millions of Americans every day, including college students. At Winston-Salem State University, nearly one in four students are eligible for or receive Supplemental Nutrition Assistance Program (SNAP) benefits. WSSU's PT and OT students lead 'Falls-Free Expo' to keep community safe on its feet. WSSU's commitment to community health was on full display as students and faculty from the Departments of PT and OT held its for the second annual Falls-Free Expo. WSSU to host adobe-sponsored rampitch business plan competition Nov 18. Big ideas, bold dreams and a little friendly competition are taking center stage at WSSU this fall. RamPitch will take place Tuesday, Nov. 18, 2025, in the Dillard Auditorium of the Anderson Center.

Quiver Quantitative
Oct 20th, 2025
ProKidney Corp. to Present Late-Breaking Phase 2 REGEN-007 Study Results at ASN Kidney Week 2025

ProKidney Corp. to present late-breaking Phase 2 REGEN-007 Study Results at ASN Kidney Week 2025. Posted: 5 days, 4 hours ago / Oct. 20, 2025 11:41 a.m. UTC ProKidney Corp. will present two posters at ASN Kidney Week 2025, highlighting key study results on CKD therapies. Quiver AI summary. ProKidney Corp., a clinical-stage company focused on chronic kidney disease (CKD), announced it will present two posters at the American Society of Nephrology's Kidney Week from November 6-9, 2025, in Houston, TX. One of the posters will feature late-breaking results from the Phase 2 REGEN-007 study on renal autologous cell therapy for diabetes and CKD. The other poster will discuss the inflammatory profile characterization of ProKidney's cell therapy candidate, rilparencel. Both presentations are scheduled for November 6 and will be accessible on the company's website after the event. ProKidney is known for its innovative cellular therapies, particularly its lead product candidate, rilparencel, which is in a Phase 3 study aimed at preserving kidney function in patients with advanced CKD and type 2 diabetes. Potential positives. * ProKidney Corp. will present a late-breaking poster on the Phase 2 REGEN-007 study results at a prestigious event, which could enhance its visibility in the nephrology community. * The inclusion of both a late-breaking and an additional poster presentation highlights the company's ongoing research and commitment to advancing treatments for chronic kidney disease. * The poster presentations reflect the scientific progress and potential impact of ProKidney's lead product candidate, rilparencel, contributing to its credibility and attractiveness to investors and stakeholders. Potential negatives. * Potential concerns about the effectiveness or safety of the lead product candidate, rilparencel, may arise from the upcoming presentation of the Phase 2 REGEN-007 study results, especially if expectations are not met. * The requirement to present a late-breaking poster might indicate that the results were not initially compelling enough for earlier dissemination, raising questions about the overall progress of the trials. What will ProKidney present at ASN Kidney Week 2025? ProKidney will present two posters, including a late-breaking poster on Phase 2 REGEN-007 study results. When is ASN Kidney Week 2025? ASN Kidney Week 2025 will be held from November 6-9, 2025, in Houston, TX. Where can I find ProKidney's poster presentations after the event? Posters will be available on ProKidney's website following the event at https://prokidney.com/our-technology/publications/. What is the focus of ProKidney's research? ProKidney focuses on chronic kidney disease (CKD) through cellular therapeutics and innovations in regenerative medicine. What is rilparencel? Rilparencel is ProKidney's lead product candidate, a first-in-class autologous cellular therapy for advanced CKD and type 2 diabetes. Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here. $PROK insider trading activity. $PROK insiders have traded $PROK stock on the open market 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales. * DARIN J. WEBER (Chief Regulatory Officer) sold 103,480 shares for an estimated $312,509 * EMPRESARIAL DE CAPITALES S.A. DE C.V. CONTROL purchased 387,393 shares for an estimated $276,366 To track insider transactions, check out Quiver Quantitative's insider trading dashboard. $PROK hedge fund activity. We have seen 28 institutional investors add shares of $PROK stock to their portfolio, and 54 decrease their positions in their most recent quarter. * BLACKROCK, INC. removed 5,000,177 shares (-73.9%) from their portfolio in Q2 2025, for an estimated $2,960,604 * MORGAN STANLEY removed 4,349,682 shares (-42.1%) from their portfolio in Q2 2025, for an estimated $2,575,446 * VANGUARD GROUP INC removed 3,643,955 shares (-69.9%) from their portfolio in Q2 2025, for an estimated $2,157,585 * JPMORGAN CHASE & CO added 1,615,243 shares (+3024.9%) to their portfolio in Q2 2025, for an estimated $956,385 * STATE STREET CORP removed 1,372,716 shares (-79.5%) from their portfolio in Q2 2025, for an estimated $812,785 * GEODE CAPITAL MANAGEMENT, LLC removed 1,310,149 shares (-56.4%) from their portfolio in Q2 2025, for an estimated $775,739 * NORTHERN TRUST CORP removed 655,832 shares (-72.3%) from their portfolio in Q2 2025, for an estimated $388,318 To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. $PROK analyst ratings. Wall Street analysts have issued reports on $PROK in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings. * UBS issued a "Buy" rating on 07/15/2025 * Citigroup issued a "Buy" rating on 07/09/2025 * B of A Securities issued a "Underperform" rating on 06/30/2025 To track analyst ratings and price targets for $PROK, check out Quiver Quantitative's $PROK forecast page. $PROK price targets. Multiple analysts have issued price targets for $PROK recently. We have seen 4 analysts offer price targets for $PROK in the last 6 months, with a median target of $7.5. * Eliana Merle from UBS set a target price of $8.0 on 07/15/2025 * Vamil Divan from Guggenheim set a target price of $7.0 on 07/14/2025 * Yigal Nochomovitz from Citigroup set a target price of $9.0 on 07/09/2025 * Jason Gerberry from B of A Securities set a target price of $1.0 on 06/30/2025 Full release. WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) - ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present two posters, including a late-breaking poster on the Phase 2 REGEN-007 study results, at the upcoming American Society of Nephrology's (ASN) Kidney Week being held from November 6-9, 2025, in Houston, TX. The titles for the accepted abstracts are provided below and accessible online at: https://www.asn-online.org/education/kidneyweek/2025/program-search-abstract.aspx Late-Breaking Poster Presentation Renal Autologous Cell Therapy in Diabetes and CKD (Phase 2 REGEN-007 Study Results) Session Title: Late-Breaking Science Posters [LB-PO] Session Date, Time: November 6, 2025 from 10:00 AM to 12:00 PM CST Poster Board #: TH-PO1203 Cell-Specific Inflammatory Profile Characterization of the Cell Therapy Candidate Rilparencel Session Title: Development, Stem Cells, and Regenerative Medicine [PO0600] Session Date, Time: November 6, 2025 from 10:00 AM to 12:00 PM CST Poster Board #: TH-PO0575 Following the event, a copy of the poster presentations will be available on the Company's website at: https://prokidney.com/our-technology/publications/ Additional information on ASN Kidney Week 2025 can be accessed online at: https://www.asn-online.org/education/kidneyweek About ProKidney Corp. ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney's lead product candidate, rilparencel (also known as REACT(R), is a first-in-class, patented, proprietary autologous cellular therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com. ProKidney Contact Ethan Holdaway [email protected] Media Contact Audra Friis [email protected] Investor Relations Contact Daniel Ferry [email protected]

INACTIVE